You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 8,465,936

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,465,936

Title:	Method for determining the sensitivity of patients suffering from a cancer disease to biological therapy
Abstract:	The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor.
Inventor(s):	Hajduch; Marian (Moravsky Beroun, CZ), Dziechciarkova; Marta (Olomouc, CZ), Radova; Lenka (Otinoves, CZ), Svoboda; Marek (Syrovice, CZ)
Assignee:	Univerzita Palackeho V Olomouci, Lekarska Fakulta (Olomouc, CZ) Masarykuv Onkologicky Ustav (Brno, CZ)
Application Number:	12/863,517
Patent Claims:	1. A method for determining the sensitivity of a breast cancer patient to trastuzumab therapy comprising: (a) obtaining a breast tumor tissue sample; (b) measuring the level of S6Kinase 1 (S6K1) protein or the level of S6K1 phosphorylation at Serine.sup.235/236 in the sample; and (c) identifying the patient as sensitive to trastuzumab therapy when the sample is negative for S6K1 protein expression or phosphorylation at Serine.sup.235/236, and identifying the patient as resistant to trastuzumab therapy when the sample is positive for S6K1 protein expression or phosphorylation at Serine.sup.235/236.

Details for Patent 8,465,936

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2028-01-25
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2028-01-25
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2028-01-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.